BIVI BIOVIE INC. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$1.49

Period return

+0.02 (+1.36%)

Volume

180.6K

2026-06-01O $1.44 H $1.49 L $1.35 C $1.49MA5 $1.45MA20 $1.45MA60 $1.44MA120 $1.37

6M · 124 barsYahoo Finance · USD2025-12-02 → 2026-06-01

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2024. 07. 01.MediumBUY2 years ago
ThinkEquity: Buy
US analyst rating / recommendation change.
2023. 12. 01.LowBUY3 years ago
Oppenheimer: Outperform
US analyst rating / recommendation change.
2023. 08. 22.LowBUY3 years ago
Cantor Fitzgerald: Overweight
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Rating & price-target changes

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Sector: Healthcare
Industry: Biotechnology
HQ: Carson City, NV, United States
Fiscal year end: —
Employees: 13
IPO date: —

View details →